Newsroom

Industry News

23 Feb

SeeThruEquity Issues Company Update on Matinas BioPharma Holdings Highlighting Aquarius Biotechnologies Acquisition

SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company update on Matinas BioPharma Holdings, Inc. (MTNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of lipid-based prescription therapeutics for the treatment...

Read more

23 Feb

Intellipharmaceutics Announces 2014 Year End Results With a 48% Reduction in Operating Loss

Intellipharmaceutics International Inc. (IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the year ended November 30, 2014. All dollar amounts referenced herein are...

Read more

23 Feb

Major Bone Marrow Transplant Event Drives Significant Interest Among Leading Transplant Physicians for Upcoming Pivotal Trial of Iomab-B

Plenary Discussions by Leading Bone Marrow Transplant Experts Provide Additional Validation of Iomab-B Clinical Development Path and Unmet Medical Need- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today a positive reception...

Read more

23 Feb

TapImmune Appoints Patrick D. Yeramian, MD, Consulting Medical Director to Lead Phase II Clinical Trials in Triple Negative Breast and HER2/neu Breast Cancer

TapImmune, (OTCBB: TPIV), an immunotherapy company specializing in the development of immunotherapeutics for the treatment of cancer including metastatic disease, is pleased to announcePatrick D. Yeramian, MD, MBA, has been appointed Consulting Medical Director. He will lead TapImmune’s clinical development programs for folate receptor alpha and Her2/neu multi-epitope cancer...

Read more

19 Feb

Nanomedicine: Nanotechnology, Biology, and Medicine Publishes Preclinical Data on Arch Therapeutics’ AC5 Surgical Hemostatic Device(TM)

Positive data from an independent third-party research group study sponsored by Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of the AC5 Surgical Hemostatic Device™, was published in the peer-reviewed journal Nanomedicine: Nanotechnology, Biology, and Medicine. The results in the manuscript, titled “AC5 Surgical Hemostat™ as an...

Read more

19 Feb

TapImmune Selects PCG Advisory Group for Investor Public and Social Media Relations

 TapImmune Inc. (OTCBB: TPIV), an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases, announced today the Company’s management team has selected New York City based PCG Advisory (PCG) as agency of record for Investor, Public, and Social Media Relations. After...

Read more

Page 227 of 274« First...102030...225226227228229...240250260...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address